Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Washington D.C., March 27, 2025 (GLOBE NEWSWIRE) -- International non-profit organization The Global Alzheimer’s Platform Foundation® (GAP) in collaboration with the Scottish Funding Council’s Brain...
-
Longeveron reaches alignment with US FDA on single, pivotal clinical trial to BLA submission for cell therapy for treatment of Alzheimer's disease.
-
Alzheimer’s disease (AD), affecting around 6.9 million people in the US, is ranked as the seventh leading cause of death and is the most common cause of dementia among older adults.AD begins with...
-
Longeveron positive Phase 2 clinical trial data in Alzheimer's disease published in peer reviewed journal Nature Medicine.
-
Longeveron to present at the Roth investor conference taking place March 17-18, 2025. Company fireside chat Tuesday, March 18th at 9:00am PT.
-
New York, USA, March 03, 2025 (GLOBE NEWSWIRE) -- LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight LEQEMBI (lecanemab) has significant...
-
Longeveron announces 2024 financial results and provides business update. Pivotal Phase 2b clinical trial achieves 90% enrollment.
-
Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025
Longeveron to report full-year 2024 financial results and provide a business update on Friday, February 28, 2025 after the U.S. financial markets close.
-
NanoNewron, a biotech company developing biologics crossing the blood-brain barrier to treat Alzheimer’s, was featured by Rutgers University Newsletters
-
CHICAGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Neurogen Biomarking, the world’s first ecosystem for memory and thinking concerns announced today that they have entered into an exclusive agreement to use...